{"code":1,"isDone":false,"toInsertArticleList":[{"createdTime":"2020-12-01 22:32:51","updatedTime":"2020-12-01 22:32:51","title":"不忘初“心”，理想降糖一定要知道这两点！","link":"http://weixin.sogou.com/weixin?type=2&query=%E5%8C%BB%E5%AD%A6%E7%95%8C+%E4%B8%8D%E5%BF%98%E5%88%9D%E2%80%9C%E5%BF%83%E2%80%9D%EF%BC%8C%E7%90%86%E6%83%B3%E9%99%8D%E7%B3%96%E4%B8%80%E5%AE%9A%E8%A6%81%E7%9F%A5%E9%81%93%E8%BF%99%E4%B8%A4%E7%82%B9%EF%BC%81","description":"<div><div><div id=\"media\" class=\"rich_media_thumb_wrp\">\n\n            <img class=\"rich_media_thumb\" src=\"http://content.sov5.cn/mmbiz_jpg/a1xwNbPmyopvgMhaQSSf7M8jWwy92dq0pWMBS8t9YXPxAtxWEibgsB6upF74SII34CreHqexqYL1OjWibxW2yrMA?imageView2/1/w/600\">\n        </div>\n    \n\n    \n\n    <div class=\"rich_media_content\" id=\"js_content\">\n                    \n\n                    \n\n                    \n                    \n                    <section yne-bulb-block=\"paragraph\"><section style=\"text-align: center;margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><img class=\"rich_pages js_insertlocalimg\" data-ratio=\"0.3333333333333333\" data-s=\"300,640\" data-type=\"png\" data-w=\"900\" style=\"letter-spacing: 0.544px; max-width: 600px\" src=\"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_png/a1xwNbPmyorS4PggDpXqpicD8J3D30x0qz8wxx0IxiaV6ddh7j6PABXqreL16wWiciaktlibvT60APRvH8Ob72XtplA/640?wx_fmt=png\"><em><strong><span style=\"font-size: 14px;color: rgb(136, 136, 136);\">不忘初“心”，理想降糖一定要知道这两点！</span></strong></em></section><section style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><br></section><section style=\"margin-top: 16px;margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-family:微软雅黑,sans-serif;\"></span></section><section style=\"margin-top: 16px;margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-size: 15px;font-family: 微软雅黑, sans-serif;\">人类与糖尿病的“拉锯战”持续已久。而在我国，糖尿病流行趋势不断呈线性增长，中国已然成为全球糖尿病人数最多的国家</span><span style=\"font-family: 微软雅黑, sans-serif;font-size: 10px;\"><sup>[1]</sup></span><span style=\"font-size: 15px;font-family: 微软雅黑, sans-serif;\">。虽然形势如此严峻，但中国糖尿病患者的知晓率、治疗率和控制率都偏低<sup>[2]</sup>。结合国际权威指南与我国国情，中国的糖尿病治疗将何去何从？今年中华医学会糖尿病学分会</span><span style=\"font-size: 15px;font-family: 微软雅黑, sans-serif;color: rgb(136, 136, 136);\">（CDS）</span><span style=\"font-size: 15px;font-family: 微软雅黑, sans-serif;\">第二十四次全国学术会或许能给我们以提示。</span></section><section style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-family: 微软雅黑, sans-serif;font-size: 15px;\"> </span></section><section style=\"text-align: center;margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-size: 17px;\"><strong><span style=\"font-family: 微软雅黑, sans-serif;color: rgb(192, 0, 0);\">结合需求，防治疗惰性早联合</span></strong></span></section><section style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-family: 微软雅黑, sans-serif;font-size: 15px;\"> </span></section><section style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-size: 15px;font-family: 微软雅黑, sans-serif;\">今年的CDS大会上，复旦大学附属华山医院的李益明教授介绍到，治疗惰性是血糖控制不佳、心血管事件和死亡风险增加的主要原因<sup>[3]</sup>，也是中国糖尿病治疗面临的挑战之一<sup>[4]</sup>。随着现代医学的发展，到2020年， 最新版的美国糖尿病协会科学年会</span><span style=\"font-size: 15px;font-family: 微软雅黑, sans-serif;color: rgb(136, 136, 136);\">（ADA）</span><span style=\"font-size: 15px;font-family: 微软雅黑, sans-serif;\">指南也开始强调关注治疗惰性，强调早期联合、起始强化治疗的重要性。</span></section><section style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-family: 微软雅黑, sans-serif;font-size: 15px;\"> </span></section><section style=\"text-align: center;margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><img class=\"rich_pages\" data-ratio=\"0.75\" data-s=\"300,640\" data-type=\"jpeg\" data-w=\"1280\" style=\"max-width: 600px\" src=\"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_jpg/a1xwNbPmyopvgMhaQSSf7M8jWwy92dq0r9SzsicoaFiajIeLAtnkibMia9ibCM27O53InAs5mOChVWeQF5ZZoJdBDdA/640?wx_fmt=jpeg\"></section><section style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-family: 微软雅黑, sans-serif;font-size: 12px;color: rgb(136, 136, 136);\"></span></section><section style=\"text-align: center;margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-family: 微软雅黑, sans-serif;font-size: 12px;color: rgb(136, 136, 136);\">图1：李益明教授现场汇报图</span></section><section style=\"text-align: center;margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-family: 微软雅黑, sans-serif;font-size: 15px;\"> </span></section><section style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-size: 15px;font-family: 微软雅黑, sans-serif;\">2型糖尿病</span><span style=\"font-size: 15px;font-family: 微软雅黑, sans-serif;color: rgb(136, 136, 136);\">（T2DM）</span><span style=\"font-size: 15px;font-family: 微软雅黑, sans-serif;\">患者存在临床惰性主要表现在以下几点：起始强化治疗的患者比例低，且起始时间明显滞后。面对临床惰性这一挑战，患者、医疗保健系统、和临床医生需共同协作，对疾病进行规范化管理<sup>[5]</sup>。</span></section><section style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-family: 微软雅黑, sans-serif;font-size: 15px;\"> </span></section><section style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-size: 15px;font-family: 微软雅黑, sans-serif;\">对此，2020ADA指南建议定期评估、及时调整治疗方案。同时表明，当二甲双胍单药治疗糖尿病糖化血红蛋白</span><span style=\"font-size: 15px;font-family: 微软雅黑, sans-serif;color: rgb(136, 136, 136);\">（HbA<sub>1c</sub>）</span><span style=\"font-size: 15px;font-family: 微软雅黑, sans-serif;\">不达标时，推荐患者根据不同需求尽早联合药物治疗，从而提高T2DM患者HbA<sub>1c</sub>达标率。</span></section><section style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-family: 微软雅黑, sans-serif;font-size: 15px;\"> </span></section><section style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-size: 15px;\"><span style=\"font-family: 微软雅黑, sans-serif;\">心血管疾病是中国T2DM患者最主要的合并症和死亡原因</span><sup>[6]</sup><span style=\"font-family: 微软雅黑, sans-serif;\"><span style=\"font-family: 微软雅黑, sans-serif;font-size: 15px;\">，C</span>APTURE 研究表示，全球T2DM患者的心血管疾病患病率约为1/3，而动脉粥样硬化性心血管疾病</span></span><span style=\"font-family: 微软雅黑, sans-serif;font-size: 15px;color: rgb(136, 136, 136);\">（ASCVD）</span><span style=\"font-family: 微软雅黑, sans-serif;font-size: 15px;color: rgb(0, 0, 0);\">的</span><span style=\"font-size: 15px;\"><span style=\"font-family: 微软雅黑, sans-serif;\">患病率高达八九成</span><sup>[7-8]</sup><span style=\"font-family: 微软雅黑, sans-serif;\">。那么这一类T2DM患者应如何联合药物治疗呢？</span></span></section><section style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-family: 微软雅黑, sans-serif;font-size: 15px;\"> </span></section><section style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-size: 15px;font-family: 微软雅黑, sans-serif;\">根据此次CDS最新公布的2020年新版的中国2型糖尿病防治指南中更新的糖尿病治疗路径</span><span style=\"font-size: 15px;font-family: 微软雅黑, sans-serif;color: rgb(136, 136, 136);\">（见图2）</span><span style=\"font-size: 15px;font-family: 微软雅黑, sans-serif;\">，合并ASCVD或有高危因素、心衰</span><span style=\"font-size: 15px;font-family: 微软雅黑, sans-serif;color: rgb(136, 136, 136);\">（HF）</span><span style=\"font-size: 15px;font-family: 微软雅黑, sans-serif;\">、慢性肾病</span><span style=\"font-size: 15px;font-family: 微软雅黑, sans-serif;color: rgb(136, 136, 136);\">（CKD）</span><span style=\"font-size: 15px;font-family: 微软雅黑, sans-serif;\">患者分别有对应的强化联合治疗建议。</span></section><section style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-family: 微软雅黑, sans-serif;font-size: 15px;\"> </span></section><section style=\"text-align: center;margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><img class=\"rich_pages\" data-ratio=\"0.5294784580498866\" data-s=\"300,640\" data-type=\"png\" data-w=\"882\" style=\"max-width: 600px\" src=\"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_png/a1xwNbPmyopvgMhaQSSf7M8jWwy92dq0AEuAfqwEgDm7J5CB1Z8I93raUIHdeUKVMYPLc5kicMn05FfFrfIGhvw/640?wx_fmt=png\"></section><section style=\"text-align: center;margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"background-color: white;color: gray;font-family: 微软雅黑, sans-serif;font-size: 12px;\">图2：2020版中国2型糖尿病防治指南——治疗路径</span><br></section><section style=\"text-align: center;margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"background-color: white;color: gray;font-family: 微软雅黑, sans-serif;font-size: 12px;\"><br></span></section><section style=\"text-align: justify;margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-family: 微软雅黑, sans-serif;color: gray;background: white;font-size: 12px;\">注：a，高危因素指年龄≥55岁伴以下至少一项：冠状动脉或颈动脉或下肢动脉狭窄≥50%，左心室肥厚；b，通常选用基础胰岛素；c，加用具有ASCVD、心衰或CKD获益证据的GLP-1RA或SGLT2i；d，有心衰者不用TZD</span></section><section style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-family: 微软雅黑, sans-serif;font-size: 15px;\"> </span></section><section style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-size: 15px;\"><span style=\"font-family: 微软雅黑, sans-serif;\">结合2020ADA指南与此次公布的2020中国2型糖尿病防治指南更新要点，对于<span style=\"color: black;\">合并</span></span><span style=\"font-family: 微软雅黑, sans-serif;color: black;\">ASCVD或心血管风险高危的T2DM患者，推荐不论其HbA<sub>1c</sub>是否达标，只要没有禁忌证都应在二甲双胍的基础上加用具有ASCVD获益证据的GLP-1RA或</span></span><span style=\"font-family: 微软雅黑, sans-serif;font-size: 15px;color: rgb(0, 0, 0);\">SGLT-2i</span><span style=\"font-size: 15px;font-family: 微软雅黑, sans-serif;\">。</span></section><section style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-family: 微软雅黑, sans-serif;font-size: 15px;\"> </span></section><section style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-family: 微软雅黑, sans-serif;font-size: 15px;\">如果患者不伴高风险因素或确诊的ASCVD、HF、或者CKD，在选择适合的治疗药物时，还应考虑其他因素，如低血糖风险、对体重的影响、不良反应、费用、患者偏好<sup>[9]</sup>。</span></section><section style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-family: 微软雅黑, sans-serif;font-size: 15px;\"> </span></section><section style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-size: 15px;font-family: 微软雅黑, sans-serif;\">其中低血糖是T2DM治疗中常见的不良反应，会增加T2DM患者微血管疾病和大血管疾病风险<sup>[10-11]</sup>。对于这一类患者，2020ADA指南提出，如患者HbA<sub>1c</sub>不达标且强烈需要减少低血糖风险，推荐优先联合低血糖风险低的药物，包括GLP-1RA、</span><span style=\"font-family: 微软雅黑, sans-serif;font-size: 15px;color: rgb(0, 0, 0);\">DPP-4i</span><span style=\"font-size: 15px;font-family: 微软雅黑, sans-serif;\">、SGLT-2i和</span><span style=\"font-family: 微软雅黑, sans-serif;font-size: 15px;color: rgb(0, 0, 0);\">TZD</span><span style=\"font-size: 15px;font-family: 微软雅黑, sans-serif;\">。</span></section><section style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-family: 微软雅黑, sans-serif;font-size: 15px;\"> </span></section><section style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-size: 15px;font-family: 微软雅黑, sans-serif;\">除此之外，肥胖也是T2DM患者面临的严峻问题。中国T2DM合并超重/肥胖患者的比例为59.3%<sup>[12]</sup>。体重指数</span><span style=\"font-size: 15px;font-family: 微软雅黑, sans-serif;color: rgb(136, 136, 136);\">（BMI）</span><span style=\"font-size: 15px;font-family: 微软雅黑, sans-serif;\">越高，T2DM患者的心血管风险因素越难控制<sup>[13]</sup>。因此，就减重而言，2020 ADA 指南推荐，对于强烈需要减少体重增长或促进减重的患者，二甲双胍治疗不达标者优先推荐联合减重疗效好的GLP-1RA或SGLT-2i。</span></section><section style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-family: 微软雅黑, sans-serif;font-size: 15px;\"> </span></section><section style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-size: 15px;font-family: 微软雅黑, sans-serif;\">GLP-1RA作为新型降糖药处在推荐当中，地位渐长。根据以LEADER研究为首的相关循证证据，GLP-1RA利拉鲁肽降低T2DM患者的MACE风险及心血管死亡风险</span><span style=\"font-family: 微软雅黑, sans-serif;font-size: 15px;color: rgb(136, 136, 136);\">（见图3）</span><span style=\"font-size: 15px;font-family: 微软雅黑, sans-serif;\">，并且不增加因心衰引起住院的风险，还可以显著降低肾脏事件风险，并持久稳定的减轻T2DM患者体重<sup>[14]</sup></span><span style=\"font-family: 微软雅黑, sans-serif;font-size: 15px;color: rgb(136, 136, 136);\">（见图4）</span><span style=\"font-size: 15px;\"><span style=\"font-family: 微软雅黑, sans-serif;color: black;\">。同时，还有研究发现利拉鲁肽发生低血糖风险极低</span><sup><span style=\"font-family: 微软雅黑, sans-serif;\">[15]</span></sup><span style=\"font-family: 微软雅黑, sans-serif;\">。</span></span></section><section style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-family: 微软雅黑, sans-serif;font-size: 15px;\"> </span></section><section style=\"text-align: center;margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><img class=\"rich_pages\" data-ratio=\"0.3239277652370203\" data-s=\"300,640\" data-type=\"png\" data-w=\"886\" style=\"max-width: 600px\" src=\"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_png/a1xwNbPmyopvgMhaQSSf7M8jWwy92dq0uicOIjFz5sJlKoK03sTOQeLEDfnblwxVJuOjeNeRdd7FsHqC6LEpecA/640?wx_fmt=png\"></section><section style=\"text-align: justify;margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-family: 微软雅黑, sans-serif;color: rgb(136, 136, 136);font-size: 12px;\">图3：LEADER研究表明利拉鲁肽显著降低MACE风险13%、心血管死亡风险22%</span></section><section style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-family: 微软雅黑, sans-serif;color: rgb(136, 136, 136);font-size: 12px;\"> </span></section><section style=\"text-align: center;margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><img class=\"rich_pages\" data-ratio=\"0.4\" data-s=\"300,640\" data-type=\"png\" data-w=\"875\" style=\"max-width: 600px\" src=\"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_png/a1xwNbPmyopvgMhaQSSf7M8jWwy92dq0ccTtF3xptX91xYkrEhHicEpia9WG8emMEIKGKjUQiaFaIbYcFsChHnAiaw/640?wx_fmt=png\"></section><section style=\"text-align: justify;margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-family: 微软雅黑, sans-serif;color: rgb(136, 136, 136);font-size: 12px;\">图4：LEADER研究表明利拉鲁肽可持久稳定的减轻T2DM患者体重</span></section><section style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-family: 微软雅黑, sans-serif;font-size: 15px;\"> </span></section><section style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-size: 15px;font-family: 微软雅黑, sans-serif;\">综合2020 ADA 指南、2020中国2型糖尿病防治指南对各类患者的联合治疗推荐及循证证据，可以看出GLP-1RA利拉鲁肽在多种类型的T2DM患者治疗中均具有一定的优势，能给T2DM患者带来多重获益。</span></section><section style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-family: 微软雅黑, sans-serif;font-size: 15px;\"> </span></section><section style=\"text-align: center;margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-size: 17px;\"><strong><span style=\"font-family: 微软雅黑, sans-serif;color: rgb(192, 0, 0);\">从“心”出发，糖尿病管理新篇章</span></strong></span></section><section style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-family: 微软雅黑, sans-serif;font-size: 15px;\"> </span></section><section style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-size: 15px;font-family: 微软雅黑, sans-serif;\">如今，心血管获益的循证证据将GLP-1RA在国际指南中的地位大大提升，然而，不是从一开始，降糖药物的心血管安全性就如此重要……</span></section><section style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-family: 微软雅黑, sans-serif;font-size: 15px;\"> </span></section><section style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-size: 15px;font-family: 微软雅黑, sans-serif;\">追溯到2008年，美国食品药品监督管理局</span><span style=\"font-size: 15px;font-family: 微软雅黑, sans-serif;color: rgb(136, 136, 136);\">（FDA）</span><span style=\"font-size: 15px;font-family: 微软雅黑, sans-serif;\">第一次制定评估降糖药物心血管安全性的行业标准，规定企业应当确保新型降糖药物不会导致心血管疾病风险的明显升高。从那时起，相关的研究逐渐丰富，也为如今在各大指南中地位升高的GLP-1 RA提供了有力的循证证据。2020新公布的中国2型糖尿病防治指南还为合并ASCVD或有高危因素、心衰、慢性肾病</span><span style=\"font-size: 15px;font-family: 微软雅黑, sans-serif;color: rgb(136, 136, 136);\">（CKD）</span><span style=\"font-size: 15px;font-family: 微软雅黑, sans-serif;\">的患者更新了治疗路径。GLP-1RA就是此次对于合并ASCVD或有高危因素，及CKD患者的联合用药推荐之一。</span></section><section style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-family: 微软雅黑, sans-serif;font-size: 15px;\"> </span></section><section style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-family: 微软雅黑, sans-serif;font-size: 15px;\">大会上，贵州医科大学附属医院时立新教授回顾了自2008年以后所进行的心血管结局研究</span><span style=\"font-family: 微软雅黑, sans-serif;font-size: 15px;color: rgb(136, 136, 136);\">（CVOT）</span><span style=\"font-family: 微软雅黑, sans-serif;font-size: 15px;\">，一共有28项研究，其中有23项已经完成，并陆续发布了结果，给糖尿病治疗领域带来了很多颠覆性的变化和启示。</span></section><section style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-family: 微软雅黑, sans-serif;font-size: 15px;\"> </span></section><section style=\"text-align: center;margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><img class=\"rich_pages\" data-ratio=\"0.749802683504341\" data-s=\"300,640\" data-type=\"jpeg\" data-w=\"1267\" style=\"max-width: 600px\" src=\"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_jpg/a1xwNbPmyopvgMhaQSSf7M8jWwy92dq0Ptg5cPCNspBXUUfmaAGAuE4uO0YBnxLvj0dwf9vOgQSEIWKRJUrwBw/640?wx_fmt=jpeg\"></section><section style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-family: 微软雅黑, sans-serif;font-size: 12px;\"></span></section><section style=\"text-align: center;margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-family: 微软雅黑, sans-serif;color: gray;font-size: 12px;\"> 图5：时立新教授现场汇报图</span></section><section style=\"text-align: center;margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-family: 微软雅黑, sans-serif;font-size: 15px;\"> </span></section><section style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-family: 微软雅黑, sans-serif;font-size: 15px;\">在众多相关研究中，不得不提的就是LEADER研究，这是一项国际性、多中心、随机、双盲、安慰剂对照的长期随访3B期临床研究，旨在伴CVD高风险的成年T2DM患者中，评估标准治疗联合利拉鲁肽或安慰剂治疗心血管事件发生情况。</span></section><section style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-family: 微软雅黑, sans-serif;font-size: 15px;\"> </span></section><section style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-size: 15px;font-family: 微软雅黑, sans-serif;\">LEADER研究表明<sup>[14]</sup>，利拉鲁肽可显著降低目标人群MACE</span><span style=\"font-size: 15px;font-family: 微软雅黑, sans-serif;color: rgb(136, 136, 136);\">（主要心血管事件）</span><span style=\"font-size: 15px;font-family: 微软雅黑, sans-serif;\">风险、心血管死亡及全因死亡风险，改善硬终点。因此，对于糖尿病合并ASCVD或ASCVD高危因素的患者，在给予标准化心血管保护药物治疗的基础上，使用利拉鲁肽可进一步降低心血管终点事件发生风险。</span></section><section style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-family: 微软雅黑, sans-serif;font-size: 15px;\"> </span></section><section style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-family: 微软雅黑, sans-serif;font-size: 15px;\">由于得到有力证据的支撑，利拉鲁肽目前已成为被证实可减少心血管死亡和全因死亡的GLP-1 RA类药物，并且已经纳入心血管适应症的降糖药物。</span></section><section style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-family: 微软雅黑, sans-serif;font-size: 15px;\"> </span></section><section style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-size: 15px;font-family: 微软雅黑, sans-serif;\">汇总各项对LEADER研究数据进行的事后分析，我们还可以得知：利拉鲁肽的心血管获益独立于低血糖事件减少、血脂水平等代谢指标以及是否应用他汀。且利拉鲁肽减少心肌梗死风险与心肌梗死分型无关；利拉鲁肽获益与基础血管病变状态无关。这就提示我们，其心血管获益存在自身特殊的作用机制。</span></section><section style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-family: 微软雅黑, sans-serif;font-size: 15px;\"> </span></section><section style=\"text-align: center;margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-size: 17px;color: rgb(204, 0, 0);\"><strong><span style=\"font-family: 微软雅黑, sans-serif;\">小结</span></strong></span></section><section style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-family: 微软雅黑, sans-serif;font-size: 15px;\"> </span></section><section style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"font-size: 15px;\"><span style=\"font-family: 微软雅黑, sans-serif;\">我国糖尿病形势愈发严峻，治疗惰性是目前中国糖尿病治疗面临的挑战之一。为解决此问题，临床医生应及时调整治疗方案，结合患者不同需求，对二甲双胍治疗不达标患者及时联合其他药物，起始强化治疗。在药物联合选择方面，新型降糖药的优势愈发明显，也受到了指南的大力推荐，尤其是还能带来心血管获益的GLP</span>‑<span style=\"font-family: 微软雅黑, sans-serif;\">1RA或SGLT-2i。以LEADER研究为首循证证据显示，GLP-1 RA</span>利拉鲁肽具有高效降糖、低血糖风险低、减轻体重等显著特性，并还能给患者带来显著性的心血管获益，是糖尿病患者的优选治疗方案之一，也期待这种新型降糖药在未来的临床中可以让更多<span style=\"font-family: 微软雅黑, sans-serif;\">T2DM患者获益</span>！</span></section><section style=\"text-align: center;margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><br></section><section yne-bulb-block=\"paragraph\" style=\"max-width: 100%;font-family: -apple-system-font, BlinkMacSystemFont, \" helvetica neue sc sans gb yahei ui arial sans-serif normal border-box break-word><section style=\"max-width: 100%;box-sizing: border-box;font-family: -apple-system-font, BlinkMacSystemFont, Arial, sans-serif;overflow-wrap: break-word !important;\"><section style=\"max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;\"><section style=\"max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;\"><section style=\"max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;\"><section style=\"margin: 1em auto;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;\"><section style=\"margin-right: auto;margin-left: auto;padding: 1em;max-width: 100%;box-sizing: border-box;background: none 0% 0% / auto repeat scroll padding-box border-box rgb(240, 240, 240);height: 10em;line-height: 1.5em;overflow: auto;overflow-wrap: break-word !important;\"><section style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><strong><span style=\"color: rgb(136, 136, 136);font-size: 12px;text-align: left;letter-spacing: 0.544px;\">参考文献：</span></strong></section><section style=\"box-sizing: border-box;font-size: 16px;\"><section style=\"box-sizing: border-box;\" powered-by=\"xiumi.us\"><section style=\"box-sizing: border-box;font-size: 16px;\"><section style=\"box-sizing: border-box;\" powered-by=\"xiumi.us\"><section style=\"white-space: normal;box-sizing: border-box;margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"box-sizing: border-box;font-size: 12px;color: rgb(136, 136, 136);\">1. 全球糖尿病概览（第九版），2019.</span></section><section style=\"white-space: normal;box-sizing: border-box;margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"box-sizing: border-box;font-size: 12px;color: rgb(136, 136, 136);\">2. Limin Wang, et al. JAMA. 2017;317(24):2515-2523.</span></section><section style=\"white-space: normal;box-sizing: border-box;margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"box-sizing: border-box;font-size: 12px;color: rgb(136, 136, 136);\">3. Brunton S, et al. Clin Diabetes. 2019 Apr;37(2):105-106.</span></section><section style=\"white-space: normal;box-sizing: border-box;margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"box-sizing: border-box;font-size: 12px;color: rgb(136, 136, 136);\">4. Chan JC, et al. Lancet Diabetes Endocrinol. 2014 Dec;2(12):969-79.</span></section><section style=\"white-space: normal;box-sizing: border-box;margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"box-sizing: border-box;font-size: 12px;color: rgb(136, 136, 136);\">5. Okemah J, et al. Ady Ther(2018)35:1735-1745</span></section><section style=\"white-space: normal;box-sizing: border-box;margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"box-sizing: border-box;font-size: 12px;color: rgb(136, 136, 136);\">6. Bragg F, et al. JAMA. 2017 Jan 17;317(3):280-289.</span></section><section style=\"white-space: normal;box-sizing: border-box;margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"box-sizing: border-box;font-size: 12px;color: rgb(136, 136, 136);\">7. Mosenzon O, et al. CAPTURE Abstract 158. Presentedat the 56th EASD on 24 September 2020.</span></section><section style=\"white-space: normal;box-sizing: border-box;margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"box-sizing: border-box;font-size: 12px;color: rgb(136, 136, 136);\">8. Hong Tianpei., et al. CAPTURE. GW-ICC 2020 Poster:GW31 –e1199.</span></section><section style=\"white-space: normal;box-sizing: border-box;margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"box-sizing: border-box;font-size: 12px;color: rgb(136, 136, 136);\">9. Diabetes Care. 2020; 43(Supplement 1): S1-S212.</span></section><section style=\"white-space: normal;box-sizing: border-box;margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"box-sizing: border-box;font-size: 12px;color: rgb(136, 136, 136);\">10. Zhao,et al.Diabetes Care.2012;35:1126-32.   </span></section><section style=\"white-space: normal;box-sizing: border-box;margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"box-sizing: border-box;font-size: 12px;color: rgb(136, 136, 136);\">11. Eur Heart J. 2013 Oct;34(40)3137-44</span></section><section style=\"white-space: normal;box-sizing: border-box;margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"box-sizing: border-box;font-size: 12px;color: rgb(136, 136, 136);\">12. Wang L, et al. Jama.2017;317(24):2515-2523.</span></section><section style=\"white-space: normal;box-sizing: border-box;margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"box-sizing: border-box;font-size: 12px;color: rgb(136, 136, 136);\">13. Masmiquel, et al. CardiovascDiabetol. 2016; 15: 29.</span></section><section style=\"white-space: normal;box-sizing: border-box;margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"box-sizing: border-box;font-size: 12px;color: rgb(136, 136, 136);\">14. Steven P. Marso, et al. N Engl J Med2016;375:311-22.</span></section><section style=\"white-space: normal;box-sizing: border-box;margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><span style=\"box-sizing: border-box;font-size: 12px;color: rgb(136, 136, 136);\">15. Nauck et al. Diabetes Care 2009;32:84–90.</span></section></section></section></section></section></section></section></section></section></section></section><section style=\"max-width: 100%;text-align: center;clear: both;margin-left: 8px;margin-right: 8px;line-height: 1.75em;box-sizing: border-box !important;overflow-wrap: break-word !important;\"><br></section></section><section><section><p style=\"margin-left: 8px;margin-right: 8px;line-height: 1.5em;\"><span style=\"font-family: -apple-system-font, BlinkMacSystemFont, \" helvetica neue sc sans gb yahei ui arial sans-serif rgb>来源：医学界</span></p></section></section><section><section><p style=\"margin-left: 8px;margin-right: 8px;line-height: 1.5em;\"><span style=\"font-size: 12px;color: rgb(136, 136, 136);\">校对：臧恒佳<br style=\"max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;\"></span></p></section></section><section><section><p style=\"margin-left: 8px;margin-right: 8px;line-height: 1.5em;\"><span style=\"font-size: 12px;color: rgb(136, 136, 136);\">责编：潘颖</span></p></section></section><section data-role=\"outer\" label=\"Powered by 135editor.com\" style=\"max-width: 100%;font-family: -apple-system-font, BlinkMacSystemFont, \" helvetica neue sc sans gb yahei ui arial sans-serif normal border-box break-word><section data-tools=\"135编辑器\" data-id=\"90215\" data-color=\"#d7000f\" style=\"max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;\"><section style=\"max-width: 100%;text-align: center;width: 677px;font-size: 16px;color: rgb(114, 114, 114);letter-spacing: 2px;font-weight: bold;margin-left: 8px;margin-right: 8px;line-height: 1.75em;box-sizing: border-box !important;overflow-wrap: break-word !important;\"><br></section></section></section><section data-role=\"paragraph\" style=\"max-width: 100%;font-family: -apple-system-font, BlinkMacSystemFont, \" helvetica neue sc sans gb yahei ui arial sans-serif normal border-box break-word><section style=\"text-align: center;margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"><img class=\"rich_pages js_insertlocalimg\" data-ratio=\"0.5555555555555556\" data-s=\"300,640\" data-type=\"png\" data-w=\"900\" style=\"max-width: 600px\" src=\"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_png/a1xwNbPmyorS4PggDpXqpicD8J3D30x0qFwia8SITjagF67QNQiaYEUHj2a6Io5ibCrPuL3iap0USaicOibeCESbdeG5A/640?wx_fmt=png\"></section></section></section><section style=\"white-space: normal;max-width: 100%;font-family: -apple-system-font, BlinkMacSystemFont, \" helvetica neue sc sans gb yahei ui arial sans-serif rgb border-box break-word><section style=\"max-width: 100%;letter-spacing: 0.544px;display: inline-block;width: 30px;box-sizing: border-box !important;overflow-wrap: break-word !important;\"><p style=\"margin-right: 8px;margin-left: 8px;max-width: 100%;min-height: 1em;box-sizing: border-box !important;overflow-wrap: break-word !important;\"><img class=\"__bg_gif\" data-ratio=\"1\" data-type=\"gif\" data-w=\"400\" style=\"display: inline-block; vertical-align: middle; box-sizing: border-box !important; overflow-wrap: break-word !important; visibility: visible !important; width: 400px !important; max-width: 600px\" src=\"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_gif/a1xwNbPmyorVMjtSHeT1D116ticxWpGsvo7D8UTuo2WQvPhG1JP7QszTVqJwwZux2Ab8yZ5Dbib2lf6PrnBic2b0g/640?wx_fmt=gif\"><span style=\"max-width: 100%;font-size: 12px;box-sizing: border-box !important;overflow-wrap: break-word !important;\"></span></p></section><section data-brushtype=\"text\" style=\"margin-left: 5px;max-width: 100%;letter-spacing: 0.544px;display: inline-block;vertical-align: middle;font-size: 12px;box-sizing: border-box !important;overflow-wrap: break-word !important;\"><p style=\"margin-right: 8px;margin-left: 8px;max-width: 100%;min-height: 1em;box-sizing: border-box !important;overflow-wrap: break-word !important;\"><span style=\"max-width: 100%;text-align: right;font-family: mp-quote, -apple-system-font, BlinkMacSystemFont, Arial, sans-serif;box-sizing: border-box !important;overflow-wrap: break-word !important;\">点击“<strong style=\"max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;\">阅读原文</strong>”，查看更多资讯~      </span></p></section></section>\n                </div>\n\n    \n        <br>\n        <div id=\"js_toobar3\" class=\"rich_media_tool\">\n            <a target=\"_blank\" href=\"https://sensors.yishengzhan.cn/r/82\" id=\"js_view_source\" class=\"media_tool_meta meta_primary\">阅读原文</a>\n        </div>\n    \n    <br>\n\n    \n        <a target=\"_blank\" href=\"http://mp.weixin.qq.com/s?__biz=MjM5MDc3NjQwMA==&amp;mid=2926704507&amp;idx=2&amp;sn=72dbdec622482dd322b664893e0903c3&amp;chksm=8d3afa44ba4d7352cfbc56a9d331ddf20f64ab0f522bf48026411dbcb9675b76c73b5e84351c&amp;scene=0#rd\" style=\"color: blue\" class=\"media_tool_meta meta_primary\">原文</a>\n        <br>\n    \n\n    \n\n    <img alt=\"\" width=\"1px\" height=\"1px\" class=\"\" style=\"width:1px;height:1px;display:none\" src=\"http://www.jintiankansha.me/rss_static/20145/VJP5ophvcX\"></div></div>","descriptionType":"html","publishedDate":"Sat, 28 Nov 2020 13:12:00 +0000","feedId":1661,"bgimg":"http://content.sov5.cn/mmbiz_jpg/a1xwNbPmyopvgMhaQSSf7M8jWwy92dq0pWMBS8t9YXPxAtxWEibgsB6upF74SII34CreHqexqYL1OjWibxW2yrMA?imageView2/1/w/600","linkMd5":"45cfab76d8ede22b3f2ed4350a12b2ac","destWidth":600,"destHeight":600,"sourceBytes":25138,"destBytes":19388,"author":"","articleImgCdnMap":{"http://content.sov5.cn/mmbiz_jpg/a1xwNbPmyopvgMhaQSSf7M8jWwy92dq0pWMBS8t9YXPxAtxWEibgsB6upF74SII34CreHqexqYL1OjWibxW2yrMA?imageView2/1/w/600":null,"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_png/a1xwNbPmyorS4PggDpXqpicD8J3D30x0qz8wxx0IxiaV6ddh7j6PABXqreL16wWiciaktlibvT60APRvH8Ob72XtplA/640?wx_fmt=png":"https://cdn.jsdelivr.net/gh/myreaderx10/cdn40@2020_3/2020/12/01/14-33-08-184_24f2a13e816f26f1.webp","http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_jpg/a1xwNbPmyopvgMhaQSSf7M8jWwy92dq0r9SzsicoaFiajIeLAtnkibMia9ibCM27O53InAs5mOChVWeQF5ZZoJdBDdA/640?wx_fmt=jpeg":"https://cdn.jsdelivr.net/gh/myreaderx27/cdn52@2020_4/2020/12/01/14-34-05-743_b8c2dac804c43f97.webp","http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_png/a1xwNbPmyopvgMhaQSSf7M8jWwy92dq0AEuAfqwEgDm7J5CB1Z8I93raUIHdeUKVMYPLc5kicMn05FfFrfIGhvw/640?wx_fmt=png":"https://cdn.jsdelivr.net/gh/myreaderx19/cdn22@2020_4/2020/12/01/14-33-54-980_5ca342c974c8b558.webp","http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_png/a1xwNbPmyopvgMhaQSSf7M8jWwy92dq0uicOIjFz5sJlKoK03sTOQeLEDfnblwxVJuOjeNeRdd7FsHqC6LEpecA/640?wx_fmt=png":null,"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_png/a1xwNbPmyopvgMhaQSSf7M8jWwy92dq0ccTtF3xptX91xYkrEhHicEpia9WG8emMEIKGKjUQiaFaIbYcFsChHnAiaw/640?wx_fmt=png":"https://cdn.jsdelivr.net/gh/myreaderx29/cdn19@2020_4/2020/12/01/14-33-08-516_18ed2645d2016285.webp","http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_jpg/a1xwNbPmyopvgMhaQSSf7M8jWwy92dq0Ptg5cPCNspBXUUfmaAGAuE4uO0YBnxLvj0dwf9vOgQSEIWKRJUrwBw/640?wx_fmt=jpeg":"https://cdn.jsdelivr.net/gh/myreaderx4/cdn34@2020_1/2020/12/01/14-33-01-407_03802b2cc331b497.webp","http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_png/a1xwNbPmyorS4PggDpXqpicD8J3D30x0qFwia8SITjagF67QNQiaYEUHj2a6Io5ibCrPuL3iap0USaicOibeCESbdeG5A/640?wx_fmt=png":"https://cdn.jsdelivr.net/gh/myreaderx7/cdn46@2020_4/2020/12/01/14-33-18-733_5d4f2f6f7a21ec59.webp","http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_gif/a1xwNbPmyorVMjtSHeT1D116ticxWpGsvo7D8UTuo2WQvPhG1JP7QszTVqJwwZux2Ab8yZ5Dbib2lf6PrnBic2b0g/640?wx_fmt=gif":"https://cdn.jsdelivr.net/gh/myreaderx12/cdn41@2020_1/2020/12/01/14-33-11-344_043b590fe087ce48.webp","http://www.jintiankansha.me/rss_static/20145/VJP5ophvcX":null},"publishedOrCreatedDate":1606833171931}],"record":{"createdTime":"2020-12-01 22:32:51","updatedTime":"2020-12-01 22:32:51","feedId":1661,"fetchDate":"Tue, 01 Dec 2020 14:32:51 +0000","fetchMs":351,"handleMs":20,"totalMs":129866,"newArticles":0,"totalArticles":5,"status":1,"type":0,"ip":"35a12d718b8c1c7134db27a83b05145c","hostName":"europe68*","requestId":"d8d5219698724b868e3ddd2cfa6d9b78_1661","contentType":"application/rss+xml","totalBytes":257064,"bgimgsTotal":1,"bgimgsGithubTotal":0,"articlesImgsTotal":10,"articlesImgsGithubTotal":7,"successGithubMap":{"myreaderx7":1,"myreaderx27":1,"myreaderx4":1,"myreaderx10":1,"myreaderx12":1,"myreaderx29":1,"myreaderx19":1},"failGithubMap":{"myreaderx14":1}},"feed":{"createdTime":"2020-08-24 21:31:31","updatedTime":"2020-09-01 09:50:49","id":1661,"name":"医学界","url":"http://feedmaker.kindle4rss.com/feeds/yixuejiezazhi.weixin.xml","subscriber":null,"website":null,"icon":"http://www.sogou.com/images/logo/new/favicon.ico?v=4","icon_jsdelivr":"https://cdn.jsdelivr.net/gh/myreaderx61/cdn75@2020_6/2020/09/01/01-50-49-815_d24121c9beed1de6.ico","description":"《医学界》以有品位、有追求、有爱心、有水平的医务工作者为受众，以“服务医生，改善医疗”为宗旨，让行医更幸福是我们的使命，为用户提供可靠、有用、有价值观的资讯是我们的存在方式。","weekly":null,"link":null},"noPictureArticleList":[{"createdTime":"2020-12-01 22:35:01","updatedTime":"2020-12-01 22:35:01","id":null,"feedId":1661,"linkMd5":"45cfab76d8ede22b3f2ed4350a12b2ac"}],"tmpCommonImgCdnBytes":0,"tmpBodyImgCdnBytes":257064,"tmpBgImgCdnBytes":0,"extra4":{"start":1606833171247,"total":0,"statList":[{"spend":665,"msg":"获取xml内容"},{"spend":20,"msg":"解释文章"},{"spend":0,"msg":"上传封面图到cdn"},{"spend":0,"msg":"修正封面图上传失败重新上传"},{"spend":121583,"msg":"正文链接上传到cdn"}]},"extra5":10,"extra6":9,"extra7ImgCdnFailResultVector":[{"code":1,"isDone":false,"source":"http://content.sov5.cn/mmbiz_jpg/a1xwNbPmyopvgMhaQSSf7M8jWwy92dq0pWMBS8t9YXPxAtxWEibgsB6upF74SII34CreHqexqYL1OjWibxW2yrMA?imageView2/1/w/600","sourceStatusCode":200,"destWidth":600,"destHeight":600,"sourceBytes":25138,"destBytes":19388,"targetWebpQuality":75,"feedId":1661,"totalSpendMs":6503,"convertSpendMs":20,"createdTime":"2020-12-01 22:32:52","host":"us-001*","referer":"http://weixin.sogou.com/weixin?type=2&query=%E5%8C%BB%E5%AD%A6%E7%95%8C+%E4%B8%8D%E5%BF%98%E5%88%9D%E2%80%9C%E5%BF%83%E2%80%9D%EF%BC%8C%E7%90%86%E6%83%B3%E9%99%8D%E7%B3%96%E4%B8%80%E5%AE%9A%E8%A6%81%E7%9F%A5%E9%81%93%E8%BF%99%E4%B8%A4%E7%82%B9%EF%BC%81","linkMd5ListStr":"45cfab76d8ede22b3f2ed4350a12b2ac,45cfab76d8ede22b3f2ed4350a12b2ac","rawMap":{"githubUrl":"https://api.github.com/repos/myreaderx14/cdn14/contents/2020/12/01/14-32-58-531_0b911be8cd44e803.webp","resp":{"code":403,"msg":"Forbidden","body":"{\n  \"message\": \"API rate limit exceeded for user ID 68584859.\",\n  \"documentation_url\": \"https://docs.github.com/rest/overview/resources-in-the-rest-api#rate-limiting\"\n}\n","headerMap":{"access-control-allow-origin":["*"],"access-control-expose-headers":["ETag, Link, Location, Retry-After, X-GitHub-OTP, X-RateLimit-Limit, X-RateLimit-Remaining, X-RateLimit-Used, X-RateLimit-Reset, X-OAuth-Scopes, X-Accepted-OAuth-Scopes, X-Poll-Interval, X-GitHub-Media-Type, Deprecation, Sunset"],"content-security-policy":["default-src 'none'"],"content-type":["application/json; charset=utf-8"],"date":["Tue, 01 Dec 2020 14:32:58 GMT"],"referrer-policy":["origin-when-cross-origin, strict-origin-when-cross-origin"],"server":["GitHub.com"],"status":["403 Forbidden"],"strict-transport-security":["max-age=31536000; includeSubdomains; preload"],"transfer-encoding":["chunked"],"vary":["Accept-Encoding, Accept, X-Requested-With"],"x-accepted-oauth-scopes":["repo"],"x-content-type-options":["nosniff"],"x-frame-options":["deny"],"x-github-media-type":["github.v3; format=json"],"x-github-request-id":["B618:064E:12B72B:355ACD:5FC65412"],"x-oauth-scopes":["admin:enterprise, admin:gpg_key, admin:org, admin:org_hook, admin:public_key, admin:repo_hook, delete:packages, delete_repo, gist, notifications, repo, user, workflow, write:discussion, write:packages"],"x-ratelimit-limit":["60"],"x-ratelimit-remaining":["0"],"x-ratelimit-reset":["1606836433"],"x-ratelimit-used":["61"],"x-xss-protection":["1; mode=block"]},"exceptionMsg":"Unexpected code 403,url is : https://api.github.com/repos/myreaderx14/cdn14/contents/2020/12/01/14-32-58-531_0b911be8cd44e803.webp","historyStatusCode":[],"spendMs":36},"base64UserPassword":null,"token":"6b67d******************************91b08"},"githubUser":"myreaderx14","githubHttpCode":403,"extra22GetBytesInfo":"1、没有Referer字段","extra23historyStatusCode":[200],"sourceSize":"24.5 KB","destSize":"18.9 KB","compressRate":"77.1%"},{"code":1,"isDone":false,"source":"http://content.sov5.cn/mmbiz_jpg/a1xwNbPmyopvgMhaQSSf7M8jWwy92dq0pWMBS8t9YXPxAtxWEibgsB6upF74SII34CreHqexqYL1OjWibxW2yrMA?imageView2/1/w/600","sourceStatusCode":200,"destWidth":600,"destHeight":600,"sourceBytes":25138,"destBytes":19388,"targetWebpQuality":75,"feedId":1661,"totalSpendMs":834,"convertSpendMs":18,"createdTime":"2020-12-01 22:32:58","host":"us-001*","referer":"http://weixin.sogou.com/weixin?type=2&query=%E5%8C%BB%E5%AD%A6%E7%95%8C+%E4%B8%8D%E5%BF%98%E5%88%9D%E2%80%9C%E5%BF%83%E2%80%9D%EF%BC%8C%E7%90%86%E6%83%B3%E9%99%8D%E7%B3%96%E4%B8%80%E5%AE%9A%E8%A6%81%E7%9F%A5%E9%81%93%E8%BF%99%E4%B8%A4%E7%82%B9%EF%BC%81","linkMd5ListStr":"45cfab76d8ede22b3f2ed4350a12b2ac,45cfab76d8ede22b3f2ed4350a12b2ac","rawMap":{"githubUrl":"https://api.github.com/repos/myreaderx14/cdn14/contents/2020/12/01/14-32-59-445_0b911be8cd44e803.webp","resp":{"code":403,"msg":"Forbidden","body":"{\n  \"message\": \"API rate limit exceeded for user ID 68584859.\",\n  \"documentation_url\": \"https://docs.github.com/rest/overview/resources-in-the-rest-api#rate-limiting\"\n}\n","headerMap":{"access-control-allow-origin":["*"],"access-control-expose-headers":["ETag, Link, Location, Retry-After, X-GitHub-OTP, X-RateLimit-Limit, X-RateLimit-Remaining, X-RateLimit-Used, X-RateLimit-Reset, X-OAuth-Scopes, X-Accepted-OAuth-Scopes, X-Poll-Interval, X-GitHub-Media-Type, Deprecation, Sunset"],"content-security-policy":["default-src 'none'"],"content-type":["application/json; charset=utf-8"],"date":["Tue, 01 Dec 2020 14:32:59 GMT"],"referrer-policy":["origin-when-cross-origin, strict-origin-when-cross-origin"],"server":["GitHub.com"],"status":["403 Forbidden"],"strict-transport-security":["max-age=31536000; includeSubdomains; preload"],"transfer-encoding":["chunked"],"vary":["Accept-Encoding, Accept, X-Requested-With"],"x-accepted-oauth-scopes":["repo"],"x-content-type-options":["nosniff"],"x-frame-options":["deny"],"x-github-media-type":["github.v3; format=json"],"x-github-request-id":["C886:7577:42084E:918548:5FC6540D"],"x-oauth-scopes":["admin:enterprise, admin:gpg_key, admin:org, admin:org_hook, admin:public_key, admin:repo_hook, delete:packages, delete_repo, gist, notifications, repo, user, workflow, write:discussion, write:packages"],"x-ratelimit-limit":["60"],"x-ratelimit-remaining":["0"],"x-ratelimit-reset":["1606836433"],"x-ratelimit-used":["61"],"x-xss-protection":["1; mode=block"]},"exceptionMsg":"Unexpected code 403,url is : https://api.github.com/repos/myreaderx14/cdn14/contents/2020/12/01/14-32-59-445_0b911be8cd44e803.webp","historyStatusCode":[],"spendMs":46},"base64UserPassword":null,"token":"6b67d******************************91b08"},"githubUser":"myreaderx14","githubHttpCode":403,"extra22GetBytesInfo":"1、没有Referer字段","extra23historyStatusCode":[200],"sourceSize":"24.5 KB","destSize":"18.9 KB","compressRate":"77.1%"},{"code":1,"isDone":false,"source":"http://www.jintiankansha.me/rss_static/20145/VJP5ophvcX","sourceStatusCode":405,"sourceBytes":0,"destBytes":0,"feedId":1661,"totalSpendMs":1972,"convertSpendMs":0,"createdTime":"2020-12-01 22:32:59","host":"us-005*","referer":"http://weixin.sogou.com/weixin?type=2&query=%E5%8C%BB%E5%AD%A6%E7%95%8C+%E4%B8%8D%E5%BF%98%E5%88%9D%E2%80%9C%E5%BF%83%E2%80%9D%EF%BC%8C%E7%90%86%E6%83%B3%E9%99%8D%E7%B3%96%E4%B8%80%E5%AE%9A%E8%A6%81%E7%9F%A5%E9%81%93%E8%BF%99%E4%B8%A4%E7%82%B9%EF%BC%81","linkMd5ListStr":"45cfab76d8ede22b3f2ed4350a12b2ac","extra22GetBytesInfo":"1、没有Referer字段","extra23historyStatusCode":[405],"sourceSize":"0","destSize":"0"},{"code":1,"isDone":false,"source":"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_png/a1xwNbPmyopvgMhaQSSf7M8jWwy92dq0ccTtF3xptX91xYkrEhHicEpia9WG8emMEIKGKjUQiaFaIbYcFsChHnAiaw/640?wx_fmt=png","sourceStatusCode":403,"sourceBytes":0,"destBytes":0,"feedId":1661,"totalSpendMs":1320,"convertSpendMs":0,"createdTime":"2020-12-01 22:33:01","host":"us-51*","referer":"http://weixin.sogou.com/weixin?type=2&query=%E5%8C%BB%E5%AD%A6%E7%95%8C+%E4%B8%8D%E5%BF%98%E5%88%9D%E2%80%9C%E5%BF%83%E2%80%9D%EF%BC%8C%E7%90%86%E6%83%B3%E9%99%8D%E7%B3%96%E4%B8%80%E5%AE%9A%E8%A6%81%E7%9F%A5%E9%81%93%E8%BF%99%E4%B8%A4%E7%82%B9%EF%BC%81","linkMd5ListStr":"45cfab76d8ede22b3f2ed4350a12b2ac","extra22GetBytesInfo":"2、Referer字段 ： http://weixin.sogou.com/weixin?type=2&query=%E5%8C%BB%E5%AD%A6%E7%95%8C+%E4%B8%8D%E5%BF%98%E5%88%9D%E2%80%9C%E5%BF%83%E2%80%9D%EF%BC%8C%E7%90%86%E6%83%B3%E9%99%8D%E7%B3%96%E4%B8%80%E5%AE%9A%E8%A6%81%E7%9F%A5%E9%81%93%E8%BF%99%E4%B8%A4%E7%82%B9%EF%BC%81","extra23historyStatusCode":[403,403],"sourceSize":"0","destSize":"0"},{"code":1,"isDone":false,"source":"http://www.jintiankansha.me/rss_static/20145/VJP5ophvcX","sourceStatusCode":405,"sourceBytes":0,"destBytes":0,"feedId":1661,"totalSpendMs":1424,"convertSpendMs":0,"createdTime":"2020-12-01 22:33:01","host":"us-011*","referer":"http://weixin.sogou.com/weixin?type=2&query=%E5%8C%BB%E5%AD%A6%E7%95%8C+%E4%B8%8D%E5%BF%98%E5%88%9D%E2%80%9C%E5%BF%83%E2%80%9D%EF%BC%8C%E7%90%86%E6%83%B3%E9%99%8D%E7%B3%96%E4%B8%80%E5%AE%9A%E8%A6%81%E7%9F%A5%E9%81%93%E8%BF%99%E4%B8%A4%E7%82%B9%EF%BC%81","linkMd5ListStr":"45cfab76d8ede22b3f2ed4350a12b2ac","extra22GetBytesInfo":"1、没有Referer字段","extra23historyStatusCode":[405],"sourceSize":"0","destSize":"0"},null,null,null],"extra10_invalidATagHrefValue":{},"extra111_proxyServerAndStatMap":{"http://us-006.herokuapp.com/":{"failCount":0,"successCount":2,"resultList":[200,200]},"http://europe-25.herokuapp.com/":{"failCount":1,"successCount":1,"resultList":[200,null]},"http://us-55.herokuapp.com/":{"failCount":0,"successCount":1,"resultList":[200]},"http://us-033.herokuapp.com/":{"failCount":0,"successCount":1,"resultList":[200]},"http://us-005.herokuapp.com/":{"failCount":1,"successCount":0,"resultList":[405]},"http://us-034.herokuapp.com/":{"failCount":0,"successCount":1,"resultList":[200]},"http://us-51.herokuapp.com/":{"failCount":1,"successCount":0,"resultList":[403]},"http://us-022.herokuapp.com/":{"failCount":1,"successCount":0,"resultList":[null]},"http://us-030.herokuapp.com/":{"failCount":1,"successCount":0,"resultList":[null]},"http://us-52.herokuapp.com/":{"failCount":0,"successCount":1,"resultList":[200]},"http://us-011.herokuapp.com/":{"failCount":1,"successCount":0,"resultList":[405]}},"extra12ImgCdnSuccessResultVector":[{"code":1,"isDone":false,"source":"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_jpg/a1xwNbPmyopvgMhaQSSf7M8jWwy92dq0Ptg5cPCNspBXUUfmaAGAuE4uO0YBnxLvj0dwf9vOgQSEIWKRJUrwBw/640?wx_fmt=jpeg","sourceStatusCode":200,"destWidth":1080,"destHeight":810,"fixedGithubDest":"https://cdn.jsdelivr.net/gh/myreaderx4/cdn34@2020_1/2020/12/01/14-33-01-407_03802b2cc331b497.webp","sourceBytes":78691,"destBytes":49836,"targetWebpQuality":75,"feedId":1661,"totalSpendMs":2995,"convertSpendMs":60,"createdTime":"2020-12-01 22:32:59","host":"us-006*","referer":"http://weixin.sogou.com/weixin?type=2&query=%E5%8C%BB%E5%AD%A6%E7%95%8C+%E4%B8%8D%E5%BF%98%E5%88%9D%E2%80%9C%E5%BF%83%E2%80%9D%EF%BC%8C%E7%90%86%E6%83%B3%E9%99%8D%E7%B3%96%E4%B8%80%E5%AE%9A%E8%A6%81%E7%9F%A5%E9%81%93%E8%BF%99%E4%B8%A4%E7%82%B9%EF%BC%81","linkMd5ListStr":"45cfab76d8ede22b3f2ed4350a12b2ac","githubUser":"myreaderx4","githubHttpCode":201,"extra22GetBytesInfo":"1、没有Referer字段","extra23historyStatusCode":[200],"sourceSize":"76.8 KB","destSize":"48.7 KB","compressRate":"63.3%"},{"code":1,"isDone":false,"source":"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_png/a1xwNbPmyorS4PggDpXqpicD8J3D30x0qz8wxx0IxiaV6ddh7j6PABXqreL16wWiciaktlibvT60APRvH8Ob72XtplA/640?wx_fmt=png","sourceStatusCode":200,"destWidth":900,"destHeight":300,"fixedGithubDest":"https://cdn.jsdelivr.net/gh/myreaderx10/cdn40@2020_3/2020/12/01/14-33-08-184_24f2a13e816f26f1.webp","sourceBytes":94158,"destBytes":28036,"targetWebpQuality":75,"feedId":1661,"totalSpendMs":9374,"convertSpendMs":72,"createdTime":"2020-12-01 22:32:59","host":"us-55*","referer":"http://weixin.sogou.com/weixin?type=2&query=%E5%8C%BB%E5%AD%A6%E7%95%8C+%E4%B8%8D%E5%BF%98%E5%88%9D%E2%80%9C%E5%BF%83%E2%80%9D%EF%BC%8C%E7%90%86%E6%83%B3%E9%99%8D%E7%B3%96%E4%B8%80%E5%AE%9A%E8%A6%81%E7%9F%A5%E9%81%93%E8%BF%99%E4%B8%A4%E7%82%B9%EF%BC%81","linkMd5ListStr":"45cfab76d8ede22b3f2ed4350a12b2ac","githubUser":"myreaderx10","githubHttpCode":201,"extra22GetBytesInfo":"1、没有Referer字段","extra23historyStatusCode":[200],"sourceSize":"92 KB","destSize":"27.4 KB","compressRate":"29.8%"},{"code":1,"isDone":false,"source":"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_png/a1xwNbPmyopvgMhaQSSf7M8jWwy92dq0ccTtF3xptX91xYkrEhHicEpia9WG8emMEIKGKjUQiaFaIbYcFsChHnAiaw/640?wx_fmt=png","sourceStatusCode":200,"destWidth":875,"destHeight":350,"fixedGithubDest":"https://cdn.jsdelivr.net/gh/myreaderx29/cdn19@2020_4/2020/12/01/14-33-08-516_18ed2645d2016285.webp","sourceBytes":54138,"destBytes":23912,"targetWebpQuality":75,"feedId":1661,"totalSpendMs":6548,"convertSpendMs":16,"createdTime":"2020-12-01 22:33:03","host":"europe-25*","referer":"http://weixin.sogou.com/weixin?type=2&query=%E5%8C%BB%E5%AD%A6%E7%95%8C+%E4%B8%8D%E5%BF%98%E5%88%9D%E2%80%9C%E5%BF%83%E2%80%9D%EF%BC%8C%E7%90%86%E6%83%B3%E9%99%8D%E7%B3%96%E4%B8%80%E5%AE%9A%E8%A6%81%E7%9F%A5%E9%81%93%E8%BF%99%E4%B8%A4%E7%82%B9%EF%BC%81","linkMd5ListStr":"45cfab76d8ede22b3f2ed4350a12b2ac","githubUser":"myreaderx29","githubHttpCode":201,"extra22GetBytesInfo":"1、没有Referer字段","extra23historyStatusCode":[200],"sourceSize":"52.9 KB","destSize":"23.4 KB","compressRate":"44.2%"},{"code":1,"isDone":false,"source":"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_gif/a1xwNbPmyorVMjtSHeT1D116ticxWpGsvo7D8UTuo2WQvPhG1JP7QszTVqJwwZux2Ab8yZ5Dbib2lf6PrnBic2b0g/640?wx_fmt=gif","sourceStatusCode":200,"destWidth":400,"destHeight":400,"fixedGithubDest":"https://cdn.jsdelivr.net/gh/myreaderx12/cdn41@2020_1/2020/12/01/14-33-11-344_043b590fe087ce48.webp","sourceBytes":18415,"destBytes":23514,"targetWebpQuality":75,"feedId":1661,"totalSpendMs":12602,"convertSpendMs":120,"createdTime":"2020-12-01 22:32:59","host":"us-033*","referer":"http://weixin.sogou.com/weixin?type=2&query=%E5%8C%BB%E5%AD%A6%E7%95%8C+%E4%B8%8D%E5%BF%98%E5%88%9D%E2%80%9C%E5%BF%83%E2%80%9D%EF%BC%8C%E7%90%86%E6%83%B3%E9%99%8D%E7%B3%96%E4%B8%80%E5%AE%9A%E8%A6%81%E7%9F%A5%E9%81%93%E8%BF%99%E4%B8%A4%E7%82%B9%EF%BC%81","linkMd5ListStr":"45cfab76d8ede22b3f2ed4350a12b2ac","githubUser":"myreaderx12","githubHttpCode":201,"extra22GetBytesInfo":"1、没有Referer字段","extra23historyStatusCode":[200],"sourceSize":"18 KB","destSize":"23 KB","compressRate":"127.7%"},{"code":1,"isDone":false,"source":"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_png/a1xwNbPmyorS4PggDpXqpicD8J3D30x0qFwia8SITjagF67QNQiaYEUHj2a6Io5ibCrPuL3iap0USaicOibeCESbdeG5A/640?wx_fmt=png","sourceStatusCode":200,"destWidth":900,"destHeight":500,"fixedGithubDest":"https://cdn.jsdelivr.net/gh/myreaderx7/cdn46@2020_4/2020/12/01/14-33-18-733_5d4f2f6f7a21ec59.webp","sourceBytes":146314,"destBytes":39658,"targetWebpQuality":75,"feedId":1661,"totalSpendMs":20023,"convertSpendMs":31,"createdTime":"2020-12-01 22:32:59","host":"us-034*","referer":"http://weixin.sogou.com/weixin?type=2&query=%E5%8C%BB%E5%AD%A6%E7%95%8C+%E4%B8%8D%E5%BF%98%E5%88%9D%E2%80%9C%E5%BF%83%E2%80%9D%EF%BC%8C%E7%90%86%E6%83%B3%E9%99%8D%E7%B3%96%E4%B8%80%E5%AE%9A%E8%A6%81%E7%9F%A5%E9%81%93%E8%BF%99%E4%B8%A4%E7%82%B9%EF%BC%81","linkMd5ListStr":"45cfab76d8ede22b3f2ed4350a12b2ac","githubUser":"myreaderx7","githubHttpCode":201,"extra22GetBytesInfo":"1、没有Referer字段","extra23historyStatusCode":[200],"sourceSize":"142.9 KB","destSize":"38.7 KB","compressRate":"27.1%"},{"code":1,"isDone":false,"source":"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_png/a1xwNbPmyopvgMhaQSSf7M8jWwy92dq0AEuAfqwEgDm7J5CB1Z8I93raUIHdeUKVMYPLc5kicMn05FfFrfIGhvw/640?wx_fmt=png","sourceStatusCode":200,"destWidth":882,"destHeight":467,"fixedGithubDest":"https://cdn.jsdelivr.net/gh/myreaderx19/cdn22@2020_4/2020/12/01/14-33-54-980_5ca342c974c8b558.webp","sourceBytes":304667,"destBytes":38740,"targetWebpQuality":75,"feedId":1661,"totalSpendMs":56187,"convertSpendMs":27,"createdTime":"2020-12-01 22:32:59","host":"us-52*","referer":"http://weixin.sogou.com/weixin?type=2&query=%E5%8C%BB%E5%AD%A6%E7%95%8C+%E4%B8%8D%E5%BF%98%E5%88%9D%E2%80%9C%E5%BF%83%E2%80%9D%EF%BC%8C%E7%90%86%E6%83%B3%E9%99%8D%E7%B3%96%E4%B8%80%E5%AE%9A%E8%A6%81%E7%9F%A5%E9%81%93%E8%BF%99%E4%B8%A4%E7%82%B9%EF%BC%81","linkMd5ListStr":"45cfab76d8ede22b3f2ed4350a12b2ac","githubUser":"myreaderx19","githubHttpCode":201,"extra22GetBytesInfo":"1、没有Referer字段","extra23historyStatusCode":[200],"sourceSize":"297.5 KB","destSize":"37.8 KB","compressRate":"12.7%"},{"code":1,"isDone":false,"source":"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_jpg/a1xwNbPmyopvgMhaQSSf7M8jWwy92dq0r9SzsicoaFiajIeLAtnkibMia9ibCM27O53InAs5mOChVWeQF5ZZoJdBDdA/640?wx_fmt=jpeg","sourceStatusCode":200,"destWidth":1080,"destHeight":810,"fixedGithubDest":"https://cdn.jsdelivr.net/gh/myreaderx27/cdn52@2020_4/2020/12/01/14-34-05-743_b8c2dac804c43f97.webp","sourceBytes":82030,"destBytes":53368,"targetWebpQuality":75,"feedId":1661,"totalSpendMs":5657,"convertSpendMs":73,"createdTime":"2020-12-01 22:34:01","host":"us-006*","referer":"http://weixin.sogou.com/weixin?type=2&query=%E5%8C%BB%E5%AD%A6%E7%95%8C+%E4%B8%8D%E5%BF%98%E5%88%9D%E2%80%9C%E5%BF%83%E2%80%9D%EF%BC%8C%E7%90%86%E6%83%B3%E9%99%8D%E7%B3%96%E4%B8%80%E5%AE%9A%E8%A6%81%E7%9F%A5%E9%81%93%E8%BF%99%E4%B8%A4%E7%82%B9%EF%BC%81","linkMd5ListStr":"45cfab76d8ede22b3f2ed4350a12b2ac","githubUser":"myreaderx27","githubHttpCode":201,"extra22GetBytesInfo":"1、没有Referer字段","extra23historyStatusCode":[200],"sourceSize":"80.1 KB","destSize":"52.1 KB","compressRate":"65.1%"}],"successGithubMap":{"myreaderx7":1,"myreaderx27":1,"myreaderx4":1,"myreaderx10":1,"myreaderx12":1,"myreaderx29":1,"myreaderx19":1},"failGithubMap":{"myreaderx14":1}}